Dimensional Fund Advisors
ADMA icon

Dimensional Fund Advisors’s ADMA Biologics ADMA Stock Holding History

Dimensional Fund Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45.1M Buy
5,005,481
+169,843
+4% +$2.68M 0.01% 1554
2025
Q4 		$88.2M Buy
4,835,638
+37,364
+0.8% +$630K 0.02% 1165
2025
Q3 		$70.3M Buy
4,798,274
+35,199
+0.7% +$603K 0.02% 1315
2025
Q2 		$86.7M Sell
4,763,075
-97,239
-2% -$1.98M 0.02% 1124
2025
Q1 		$96.4M Buy
4,860,314
+191,994
+4% +$3.32M 0.02% 1005
2024
Q4 		$80.1M Buy
4,668,320
+643,661
+16% +$12.1M 0.02% 1214
2024
Q3 		$80.4M Buy
4,024,659
+866,699
+27% +$13.5M 0.02% 1198
2024
Q2 		$35.3M Sell
3,157,960
-440,076
-12% -$3.69M 0.01% 1677
2024
Q1 		$23.7M Buy
3,598,036
+106,975
+3% +$585K 0.01% 1896
2023
Q4 		$15.8M Buy
3,491,061
+561,243
+19% +$2.08M ﹤0.01% 2102
2023
Q3 		$10.5M Buy
2,929,818
+1,651,433
+129% +$6.36M ﹤0.01% 2222
2023
Q2 		$4.72M Buy
1,278,385
+1,222,854
+2,202% +$4.53M ﹤0.01% 2549
2023
Q1 		$184K Hold
55,531
– – ﹤0.01% 3220
2022
Q4 		$215 Sell
55,531
-2,648
-5% -$8.17K ﹤0.01% 3213
2022
Q3 		$141K Sell
58,179
-5,783
-9% -$13.9K ﹤0.01% 3292
2022
Q2 		$126K Buy
63,962
+6,290
+11% +$12.4K ﹤0.01% 3299
2022
Q1 		$106K Hold
57,672
– – ﹤0.01% 3387
2021
Q4 		$81K Sell
57,672
-45,546
-44% -$59.9K ﹤0.01% 3454
2021
Q3 		$117K Sell
103,218
-36,095
-26% -$50.6K ﹤0.01% 3412
2021
Q2 		$223K Sell
139,313
-12,400
-8% -$21.8K ﹤0.01% 3320
2021
Q1 		$267K Buy
+151,713
New +$347K ﹤0.01% 3242
2020
Q4 		– Sell
-11,840
Closed -$28K – 3343
2020
Q3 		$28K Buy
+11,840
New +$32.5K ﹤0.01% 3319
2019
Q2 		– Sell
-14,127
Closed -$54K – 3464
2019
Q1 		$54K Hold
14,127
– – ﹤0.01% 3407
2018
Q4 		$34K Buy
+14,127
New +$70K ﹤0.01% 3412

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Dimensional Fund Advisors's ADMA Position: Q1 2026 in Review

Dimensional Fund Advisors increased its ADMA Biologics (ADMA) stake by 3.5% in Q1 2026, buying an estimated $2.68M and bringing the position to 5,005,481 shares worth $45.1M. The position accounts for 0.01% of the portfolio, ranked #1554.

Dimensional Fund Advisors first reported a position in ADMA in Q4 2018 and has held it in 24 quarters since. The position peaked at $96.4M in Q1 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Dimensional Fund Advisors held 5,005,481 shares of ADMA Biologics worth $45.1M as of Q1 2026.
  • Dimensional Fund Advisors bought 169,843 ADMA Biologics shares in Q1 2026, an estimated $2.68M.
  • ADMA Biologics made up 0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #1554 holding.
  • Dimensional Fund Advisors first reported a position in ADMA Biologics in Q4 2018 and has held it in 24 quarters since.
  • Dimensional Fund Advisors's ADMA Biologics position peaked at $96.4M in Q1 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.